Keyphrases
Systemic Sclerosis
100%
FDA-approved Drugs
100%
Innovative Therapies
100%
Nanoparticles
100%
Inflammatory Monocytes
27%
Toll-like Receptor 2 (TLR2)
9%
STAT4
9%
Variant Allele
9%
TNIP1
9%
Induration
9%
CD163
9%
Scavenger Receptor
9%
TNFAIP3
9%
Activated Macrophages
9%
Interferon Regulatory Factor 8 (IRF8)
9%
Organ Involvement
9%
MARCOS
9%
Selective Targeting
9%
Lung Biopsy
9%
Interferon Regulatory Factor 5 (IRF5)
9%
Inflammatory Macrophages
9%
Myofibroblast
9%
Monocyte-derived Macrophages
9%
Genetic Studies
9%
Skin Biopsy
9%
National Center
9%
Visceral Organs
9%
Young Women
9%
Unmet Medical Need
9%
Mortality Rate
9%
Lesional Skin
9%
Macrophages
9%
Innate Immunity
9%
Center of Excellence
9%
Orphan Disease
9%
Organ Fibrosis
9%
Disease Outcome
9%
Improved Outcomes
9%
Process Outcomes
9%
Scleroderma
9%
Life-threatening
9%
Mouse Infection
9%
Lung Fibrosis
9%
Biochemistry, Genetics and Molecular Biology
Macrophage
100%
Immunity
100%
Innate Immunity
25%
Allele
25%
Mouse Model
25%
Mortality Rate
25%
IRF5
25%
CD163
25%
STAT4
25%
IRF8
25%
TNFAIP3
25%
Genetics
25%
MARCO
25%
Myofibroblast
25%
Scavenger Receptor
25%
TLR2
25%
Immunology and Microbiology
Systemic Scleroderma
100%
Immunity
100%
Macrophage
36%
Scleroderma
9%
Innate Immune System
9%
TLR2
9%
Mortality Rate
9%
MARCO
9%
Interferon Regulatory Factor 5
9%
STAT4
9%
IRF8
9%
CD163
9%
Mouse Model
9%
Scavenger Receptor
9%
Myofibroblast
9%
Allele
9%